(Reuters) – Moderna (NASDAQ) Inc Wednesday maintained its full-year revenue forecast for COVID-19 vaccine, at $21 Billion. The decline in cases and lower demand are a result of countries’ rush last year to obtain shots.

Company stated that it anticipates COVID’s “market dynamics” to result in slightly greater sales in the second quarter of 2022 than the first.

After their highs in 2021, sales of COVID-19 have begun to fall. Pfizer Inc (NYSE: ) kept unchanged its COVID-19 forecast.

Pfizer said Tuesday there were less chances of COVID vaccine sales exceeding its full-year forecast than with a number of forecast rises for 2021.